These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 31611360)
1. Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis. van Wijk F; Waterval J; van Aerde K; Henriet SSV; Meijer FJA; Borra LC; Aarnoutse RE; van Ingen J Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611360 [No Abstract] [Full Text] [Related]
2. Chronic otitis media caused by Mycobacterium abscessus spp. massiliense treated with tigecycline in a 10-year-old child. Myojin S; Fukuoka K; Kanemaru A; Baba S; Okamoto Y; Suzuki H; Kamada K; Yoshida A; Kikuchi K; Horikoshi Y Int J Infect Dis; 2018 Sep; 74():10-12. PubMed ID: 29966711 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease. Kang N; Jeon K; Kim H; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ; Jhun BW Chest; 2021 Aug; 160(2):436-445. PubMed ID: 33621600 [TBL] [Abstract][Full Text] [Related]
4. Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of Ignatius EH; Rimal B; Panthi CM; Belz DC; Lippincott CK; Deck DH; Serio AW; Lamichhane G mSphere; 2024 Jul; 9(7):e0038124. PubMed ID: 38980071 [TBL] [Abstract][Full Text] [Related]
5. Successful Salvage Therapy Including Tigecycline for Pediatric Bell KJ; Adams DJ; Brietzke S; Spencer SE Clin Pediatr (Phila); 2024 Mar; 63(3):300-303. PubMed ID: 37246637 [No Abstract] [Full Text] [Related]
6. No Amikacin, No Problem: a Successful Treatment Approach for Pediatric Otomastoiditis Due to Amikacin-Resistant Mycobacterium abscessus. Richter WJ; Cohen KA Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685473 [TBL] [Abstract][Full Text] [Related]
7. Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination. Pryjma M; Burian J; Thompson CJ Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760147 [No Abstract] [Full Text] [Related]
9. Comparison of two-drug combinations, amikacin/tigecycline/imipenem and amikacin/tigecycline/clarithromycin against Mycobacteroides abscessus subsp. abscessus using the in vitro time-kill assay. Portell-Buj E; Bonet-Rossinyol Q; López-Gavín A; Roman A; Fernández-Pittol M; Tudó G; Gonzalez-Martin J J Antibiot (Tokyo); 2021 Apr; 74(4):285-290. PubMed ID: 33420382 [TBL] [Abstract][Full Text] [Related]
10. Assessment of Clofazimine and TB47 Combination Activity against Mycobacterium abscessus Using a Bioluminescent Approach. Liu Y; Tan Y; Islam MM; Cao Y; Lu X; Zeng S; Hameed HMA; Zhou P; Cai X; Wang S; Mugweru JN; Zhang G; Yin H; Liu J; Nuermberger E; Zhang T Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843996 [No Abstract] [Full Text] [Related]
11. Nontuberculous mycobacterial otomastoiditis in children: four cases and a literature review. Flint D; Mahadevan M; Gunn R; Brown S Int J Pediatr Otorhinolaryngol; 1999 Dec; 51(2):121-7. PubMed ID: 10619626 [TBL] [Abstract][Full Text] [Related]
14. Three cases of otitis media caused by Mycobacterium abscessus subsp. abscessus: Importance of medical treatment and efficacy of surgery. Nishiyama Y; Nishiyama T; Kanzaki S; Oishi N; Fujioka M; Yamada H; Ebisuno C; Kaiho M; Uwamino Y; Fukano H; Hoshino Y; Hasegawa N; Ogawa K J Infect Chemother; 2021 Aug; 27(8):1251-1257. PubMed ID: 33934919 [TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex. Singh S; Bouzinbi N; Chaturvedi V; Godreuil S; Kremer L Clin Microbiol Infect; 2014 Dec; 20(12):O1124-7. PubMed ID: 25185732 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the intracellular activity of drugs against Mycobacterium abscessus using a THP-1 macrophage model. Molina-Torres CA; Tamez-Peña L; Castro-Garza J; Ocampo-Candiani J; Vera-Cabrera L J Microbiol Methods; 2018 May; 148():29-32. PubMed ID: 29626567 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of Short-Term Tigecycline-Containing Regimens for Mycobacterium abscessus Pulmonary Disease. Kim SR; Jang M; Kim SY; Kim DH; Jhun BW Antimicrob Agents Chemother; 2022 Oct; 66(10):e0077422. PubMed ID: 36165626 [TBL] [Abstract][Full Text] [Related]
18. Le Run E; Arthur M; Mainardi JL Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745387 [No Abstract] [Full Text] [Related]
19. Ex vivo infection of murine precision-cut lung tissue slices with Mycobacterium abscessus: a model to study antimycobacterial agents. Molina-Torres CA; Flores-Castillo ON; Carranza-Torres IE; Guzmán-Delgado NE; Viveros-Valdez E; Vera-Cabrera L; Ocampo-Candiani J; Verde-Star J; Castro-Garza J; Carranza-Rosales P Ann Clin Microbiol Antimicrob; 2020 Nov; 19(1):52. PubMed ID: 33222688 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of tedizolid against the Mycobacterium abscessus complex. Compain F; Soroka D; Heym B; Gaillard JL; Herrmann JL; Dorchène D; Arthur M; Dubée V Diagn Microbiol Infect Dis; 2018 Mar; 90(3):186-189. PubMed ID: 29217419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]